HBOT increases cerebral oxygen tension, creating a favorable microenvironment for NSC proliferation and upregulating BDNF transcription via HIF-1α stabilization, activating TrkB on progenitors. However, adult hippocampal neurogenesis in aged human AD is controversial, and increased BDNF after acute injury does not imply restored neurogenesis in chronic amyloid/tau disease.
Curated pathway from expert analysis
flowchart TD
A["HBOT 2.0 ATA<br/>60 min 5x/week 6 weeks"]
B["BDNF<br/>Upregulation"]
C["TrkB<br/>Receptor Activation"]
D["Hippocampal<br/>Neurogenesis"]
E["Memory<br/>Consolidation"]
A --> B
B --> C
C --> D
D --> E
style A fill:#1b5e20,stroke:#a5d6a7,color:#a5d6a7
style E fill:#1b5e20,stroke:#a5d6a7,color:#a5d6a7No linked papers recorded for this hypothesis yet.
Median TPM across 13 brain regions for BDNF from GTEx v10.
No clinical trials data linked to this hypothesis yet.
No curated ClinVar variants loaded for this hypothesis.
Run scripts/backfill_clinvar_variants.py to fetch P/LP/VUS variants.
No DepMap CRISPR Chronos data found for BDNF.
Run python3 scripts/backfill_hypothesis_depmap.py to populate.
| Prediction | Predicted | Observed | Status | Conf |
|---|---|---|---|---|
| IF 12-month-old APP/PS1 mice receive HBOT at 2.0 ATA for 60 min, 5x/week for 6 weeks, THEN hippocampal DCX+ neuroblast density will increase by ≥40% and these mice will exhibit ≥20% better performance | DCX+ cell count in dentate gyrus subgranular zone will be ≥40% higher; probe trial platform crossings will be ≥20% greater in HBOT vs control group | — no observation — | pending | 0.62 |
| IF adults aged 55-70 with confirmed amyloid pathology (PET or CSF Aβ42/Aβ40 ratio) receive HBOT at 2.0 ATA for 60 min, 5x/week for 6 weeks (30 total sessions), THEN serum BDNF levels will increase by | Serum BDNF concentration will be ≥25% higher in HBOT group vs sham, with effect size d ≥ 0.6 | — no observation — | pending | 0.55 |